Protara Therapeutics

Company snapshot

Protara is committed to advancing transformative therapies for people with cancer and rare diseases. Protara’s portfolio includes its lead program, TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer and lymphatic malformations, and IV Choline Chloride, an investigational, intravenous phospholipid substrate replacement therapy in develop

• 7 active pipeline program(s) linked via ClinicalTrials.gov.
• 2 US patent(s) indexed to this assignee profile.
• 7 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Protara Therapeutics. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Protara Therapeutics.

1. Jun 8, 2026 Clinical update

   TARA-001-301 — Phase 3

2. Jun 8, 2026 Clinical update

   Subcutaneous depot medroxyprogesterone acetate — Approved

3. Jun 8, 2026 Clinical update

   Daunorubicin — Phase 1

4. Jun 8, 2026 Clinical update

   Choline Chloride for Injection — Phase 3

5. May 26, 2026 Clinical update

   TARA-002 — Phase 2

View all clinical trial activity →

• What is Protara Therapeutics?

  Protara Therapeutics is a biotech organization headquartered in New York, USA. It trades on NYSE under ticker TARA. Primary therapeutic focus areas include Non-muscle Invasive Bladder Cancer, Intestinal Failure, Choline Deficiency, Acute Lymphocytic Leukemia, Contraception. NovaP

• Is Protara Therapeutics publicly traded?

  Yes. Protara Therapeutics is listed with ticker TARA on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Protara Therapeutics develop or market?

  We link 10 drug profile(s) where Protara Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/protara-therapeutics#company-drugs.

• What are the latest developments for Protara Therapeutics?

  In the last 12 months our linked public records show 7 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Protara Therapeutics focus on?

  Protara Therapeutics focuses on Non-muscle Invasive Bladder Cancer, Intestinal Failure, Choline Deficiency based on our analysis of their pipeline programs and drug development activities.